Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Stephen D. Wilson who wrote (936)	11/1/1999 10:16:00 AM
From: Shadow	Read Replies (1) \| Respond to of 1386

News out!! (PR NEWSWIRE) Pharmos Corporation Receives Additional Patents for Novel Dr Pharmos Corporation Receives Additional Patents for Novel Drug Delivery Technologies ISELIN, N.J., Nov. 1 /PRNewswire/ -- Pharmos Corporation (Nasdaq: PARS) announced that it has recently received, jointly with the U.S. Army, a new patent from the U.S. Patent and Trademark Office. The patent covers Submicron Emulsion (SME), a novel drug delivery technology developed by Pharmos, as vaccine adjuvants. Pharmos announced it has also received a Notice of Allowance for a new patent with claims covering SMEs as topical and transdermal delivery systems. The receipt of these patents coincides with the progression of discussions between Pharmos and several companies concerning the use of SME technologies commercially. The new patents cover additional broad therapeutic applications for medicinal emulsions not covered under patents already assigned to Pharmos, or for which Pharmos has exclusive worldwide licensing rights. In addition, receipt of the patents validates the superior bioavailability and efficacy of Pharmos' formulations compared to conventional compositions. These technology advantages were also clearly demonstrated in extensive testing by the Company. For example, nonsteroidal anti-inflammatory drugs (NSAIDs) formulated with SME technology and applied topically in animal models demonstrated significantly better penetration and site bioavailability over other routes of administration. Pharmos has an active program to develop novel drug delivery vehicles for therapeutic applications, principally involving topical treatments and transdermal applications for systemic disorders. This core technology is particularly relevant to the formulation of non-water-soluble drugs, although enhanced beneficial effects were obtained even in the case of some water-soluble drugs. Pharmos also holds issued patents to novel nanoemulsion particles grouped under the tradename EMULSOME(TM), which have solid lipid cores surrounded by phospholipid bilayers, thereby providing the advantages of both standard emulsions and liposomes. EMULSOME-based formulations have shown enhanced drug delivery and improved pre-clinical efficacy for oral and parenteral routes. Pharmos has filed a number of patents to protect various aspects of this core technology. The patents cover both pharmaceutical and cosmetic uses of the Company's drug delivery technologies. Pharmos Corporation develops and commercializes Enhanced Molecular Structures (EMS) for the ophthalmic, neurological and other key healthcare markets. Through EMS activity, the Company improves target molecules to limit or remove undesirable side effects while retaining each compound's important therapeutic benefits. Statements made in this press release related to operational expectations of the Company and to the development and commercialization of the Company's pipeline products are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties which may cause results to differ materially from those set forth in these statements. Additional economic, competitive, governmental, technological, marketing and other factors identified in Pharmos' filings with the Securities and Exchange Commission could affect such results. SOURCE Pharmos Corporation -0- 11/01/1999 /CONTACT: Gale Smith of Pharmos, 732-452-9556/ (PARS) CO: Pharmos Corporation ST: New Jersey IN: MTC SU: PDT * end of story *